• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Mayo Clinical Reviews

























































I’m a KAM. Just riding it out for a few more years. The money is great and the little to no work is also great. It’s overpaid part time job with nice benefits. You’ve got to be okay with playing the game. Makes me feel a little dirty at the end of each day. There is ZERO access here. Yep, I’m in the upper Midwest.